On the mark: genetically engineered immunotherapies for autoimmunity.

On the mark: genetically engineered immunotherapies for autoimmunity.
Curr Opin Immunol. 2019 Sep 26;61:69-73
Authors: Ellebrecht CT, Lundgren DK, Payne AS
Abstract
Current therapies for autoimmunity cause significant morbidity and mortality. Adoptive immunotherapy using genetically engineered T cells has led to durable remissions of B cell leukemias and lymphomas, raising the question of whether the approach can be modified to target autoreactive B and T cells to induce durable remissions of autoimmunity. Here we review antigen-specific approaches to modify immune cells to treat autoimmune disease. We focus on recent studies that aim to eliminate or suppress autoimmunity by targeting the disease-causing B or T cells through their B cell receptor or T cell receptor specificities.
PMID: 31563849 [PubMed - as supplied by publisher]

Source: Current Opinion in Immunology - September 25, 2019 Category: Allergy & Immunology Authors: Ellebrecht CT, Lundgren DK, Payne AS Tags: Curr Opin Immunol Source Type: research